Literature DB >> 19328689

(+/-)-Nantenine analogs as antagonists at human 5-HT(2A) receptors: C1 and flexible congeners.

Sandeep Chaudhary1, Stevan Pecic, Onica Legendre, Hérnan A Navarro, Wayne W Harding.   

Abstract

C1 and flexible analogs of (+/-)-nantenine were synthesized and evaluated for antagonist activity at human 5-HT(2A) receptors in a calcium mobilization assay. This work has resulted in the identification of the most potent 5-HT(2A) antagonist known based on an aporphine. Our results also suggest that the C1 position may be a key site for increasing 5-HT(2A) antagonist activity in this compound series. In addition, the structural rigidity of the aporphine core appears to be required for nantenine to function as a 5-HT(2A) antagonist.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19328689      PMCID: PMC2677726          DOI: 10.1016/j.bmcl.2009.03.048

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  31 in total

Review 1.  Advances in development of dopaminergic aporphinoids.

Authors:  Ao Zhang; Yi Zhang; Alan R Branfman; Ross J Baldessarini; John L Neumeyer
Journal:  J Med Chem       Date:  2007-01-25       Impact factor: 7.446

2.  Direct intramolecular arylation of unactivated arenes: application to the synthesis of aporphine alkaloids.

Authors:  Marc Lafrance; Nicole Blaquière; Keith Fagnou
Journal:  Chem Commun (Camb)       Date:  2004-10-25       Impact factor: 6.222

Review 3.  Cytotoxic and antitumor potentialities of aporphinoid alkaloids.

Authors:  C Stévigny; C Bailly; J Quetin-Leclercq
Journal:  Curr Med Chem Anticancer Agents       Date:  2005-03

Review 4.  Risperidone: a review.

Authors:  Hans-Jürgen Möller
Journal:  Expert Opin Pharmacother       Date:  2005-05       Impact factor: 3.889

5.  Aryl radical cyclizations of 1-(2'-bromobenzyl)isoquinolines with AIBN-Bu3SnH: formation of aporphines and indolo

Authors: 
Journal:  Org Lett       Date:  2000-02-10       Impact factor: 6.005

6.  5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants.

Authors:  Agnès Auclair; Candice Drouin; Susanna Cotecchia; Jacques Glowinski; Jean-Pol Tassin
Journal:  Eur J Neurosci       Date:  2004-12       Impact factor: 3.386

7.  Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.

Authors:  Edward D Levin; Susan Slade; Michael Johnson; Ann Petro; Kofi Horton; Paul Williams; Amir H Rezvani; Jed E Rose
Journal:  Eur J Pharmacol       Date:  2008-10-17       Impact factor: 4.432

Review 8.  Medicinal chemical properties of successful central nervous system drugs.

Authors:  Hassan Pajouhesh; George R Lenz
Journal:  NeuroRx       Date:  2005-10

9.  The efficient synthesis of morphinandienone alkaloids by using a combination of hypervalent iodine(III) reagent and heteropoly acid.

Authors:  Hiromi Hamamoto; Yukiko Shiozaki; Hisanori Nambu; Kayoko Hata; Hirofumi Tohma; Yasuyuki Kita
Journal:  Chemistry       Date:  2004-10-11       Impact factor: 5.236

Review 10.  5-HT3 receptors.

Authors:  Brenda Costall; Robert J Naylor
Journal:  Curr Drug Targets CNS Neurol Disord       Date:  2004-02
View more
  14 in total

1.  Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations.

Authors:  Stevan Pecic; Marie A McAnuff; Wayne W Harding
Journal:  J Enzyme Inhib Med Chem       Date:  2010-06-28       Impact factor: 5.051

2.  Cytotoxicity of aporphines in human colon cancer cell lines HCT-116 and Caco-2: an SAR study.

Authors:  Shashikanth Ponnala; Sandeep Chaudhary; Antonio González-Sarrias; Navindra P Seeram; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2011-06-15       Impact factor: 2.823

3.  Affinity of aporphines for the human 5-HT2A receptor: insights from homology modeling and molecular docking studies.

Authors:  Stevan Pecic; Pooja Makkar; Sandeep Chaudhary; Boojala V Reddy; Hernan A Navarro; Wayne W Harding
Journal:  Bioorg Med Chem       Date:  2010-06-20       Impact factor: 3.641

4.  Evaluation of structural effects on 5-HT(2A) receptor antagonism by aporphines: identification of a new aporphine with 5-HT(2A) antagonist activity.

Authors:  Shashikanth Ponnala; Junior Gonzales; Nirav Kapadia; Hernan A Navarro; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2014-03-04       Impact factor: 2.823

5.  Synthesis and evaluation of aporphine analogs containing C1 allyl isosteres at the h5-HT(2A) receptor.

Authors:  Shashikanth Ponnala; Nirav Kapadia; Sudharshan Madapa; Ian L Alberts; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2015-10-09       Impact factor: 2.823

6.  New aporphinoid 5-HT2A and α1A antagonists via structural manipulations of nantenine.

Authors:  Sandeep Chaudhary; Shashikanth Ponnala; Onica Legendre; Junior A Gonzales; Hernán A Navarro; Wayne W Harding
Journal:  Bioorg Med Chem       Date:  2011-08-18       Impact factor: 3.641

7.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Authors:  Onica Legendre; Stevan Pecic; Sandeep Chaudhary; Sarah M Zimmerman; William E Fantegrossi; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2009-11-20       Impact factor: 2.823

8.  C4 phenyl aporphines with selective h5-HT(2B) receptor affinity.

Authors:  Nirav Kapadia; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2015-07-11       Impact factor: 2.823

9.  A New Route to Azafluoranthene Natural Products via Direct Arylation.

Authors:  Shashikanth Ponnala; Wayne W Harding
Journal:  European J Org Chem       Date:  2013-01-03

10.  Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT2 and α1 receptor antagonists.

Authors:  Hui Li Heng; Chin Fei Chee; Sek Peng Chin; Yifan Ouyang; Hao Wang; Michael J C Buckle; Deron R Herr; Ian C Paterson; Stephen W Doughty; Noorsaadah Abd Rahman; Lip Yong Chung
Journal:  Medchemcomm       Date:  2018-02-26       Impact factor: 3.597

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.